ADMA vs ROL · P/E 22, rev $426.5M vs P/E 41, rev $3.39B
ADMA Biologics Inc (ADMA) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
ADMA Biologics Inc (ADMA) is a biotechnology company listed on US.
Rollins Inc (ROL) is a personal services company listed on NYSE.
Latest reported ADMA revenue for 2024-12-31 was $426.5M. Net income was $197.7M. Revenue was up 65.2% from 2023-12-31 to 2024-12-31. ADMA currently screens at market cap $4.39B and trailing P/E 21.9.
Latest reported ROL revenue for 2024-12-31 was $3.39B. Net income was $466.4M. Revenue was up 10.3% from 2023-12-31 to 2024-12-31. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
ADMA currently screens at market cap $4.39B and trailing P/E 21.9. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the ADMA and ROL stock pages for the full models.
Not investment advice.